1.Textual Research of Key Information of Classic Formula Xieqingwan Based on Ancient and Modern Literature
Yujie CHANG ; Lyuyuan LIANG ; Jialei CAO ; Xinghang LYU ; Wenxi WEI ; Xiaofang WANG ; Huizhen ZHANG ; Sai REN ; Mengqi WANG ; Bingqi WEI ; Bingxiang MA
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(4):226-234
ObjectiveThis paper aims to systematically collect and organize ancient and modern clauses and studies containing Xieqingwan, excavate and analyze the key information of Xieqingwan, and provide a reference for facilitating the development of the classic formula Xieqingwan. MethodsThe composition, dosage, decocting methods, usage, and other key information of Xieqingwan in ancient traditional Chinese medicine books were collected and analyzed by means of literature research and metrological methods. The modern clinical application of Xieqingwan was summarized. ResultsA total of 42 pieces of effective data involving 32 ancient traditional Chinese medicine books were collected. Xieqingwan was first recorded in Xiaoer Yaozheng Zhijue. The drug origin of this formula is basically clear in the ancient traditional Chinese medicine books. The modern drug usage and decocting method were as follows: Angelicae Sinensis Radix, Gentianae Radix et Rhizoma, Chuanxiong Rhizoma, Gardenia seeds, Radix et Rhizoma Rhei, Notopterygii Rhizoma et Radix, and Saposhnikoviae Radix were grounded to fine powder, decocted with honey, and finally formed into pills with the size of a chicken head (1.5 g). It was suggested that half a pill or one pill were taken for one dose with warm Lophatheri decoction and sugar. The indications and clinical application had developed from the recordings in Xiaoer Yaozheng Zhijue and evolved from pediatrics to ophthalmic otolaryngology, neurology, dermatology, digestion, and respiratory diseases. The main pathogenesis of these diseases is heat in the liver meridian and is treated. The effect of Xieqingwan is "clearing away heat and toxicity, removing fire and relaxing the bowels, and dispersing swelling and relieving pain". It is recommended to use the corresponding preparation methods in the 2020 Edition of Pharmacopoeia of the People's Republic of China. Modern clinical studies are centered around the clinical application of Xieqingwan, which is often modified and used in treating Tourette syndrome, herpes, febrile convulsion, sleepwalking, and insomnia. ConclusionThis paper conducts a thorough textual research of the key information of Xieqingwan, induces its historic evolution, and confirms its key information, so as to provide a reference for the future development of Xieqingwan.
2.Textual Research and Analysis of Historic Origin and Ancient and Modern Application of Classic Formula Shengjiangsan
Lyuyuan LIANG ; Jialei CAO ; Xinghang LYU ; Weixiao LI ; Wenxi WEI ; Bingqi WEI ; Zhe WANG ; Yiping WANG ; Bingxiang MA ; Wenli SHI
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(9):219-227
Shengjiangsan is a classic formula for treating warm diseases with wide clinical application and accurate efficacy. There are different opinions on the origin of this formula and lacks key information research on this formula. Therefore, in this study, we conducted systematic research into the historic origin, composition, and other key information of this Shengjiangsan. Results showed that Shengjiangsan has different versions, with "Neixian Fufang", "Jiawei Jianghuangwan", "Peizhensan", and "Taijiwan" being the same formula with different names. Shengjiangsan was first recorded as "Neixian Fufang" in Wanbing Huichun written by GONG Tingxian from the Ming dynasty, inherited and developed by YANG Lishan from Qing dynasty, and has been passed down to modern times. Pills and powder are two main forms of Shengjiangsan, and powder has become more popular nowadays. According to the measurement system of Ming and Qing dynasties, the recommended dosage and usage of Shengjiangsan are as follows. For the pill version of Shengjiangsan, Bombyx Batryticatus of 74.6 g, Curcumae Longae Rhizoma of 9.325 g, Cicadae Periostracum of 9.325 g, and Rhei Radix et Rhizoma of 149.2 g were processed into pills for preparation. Single dosage is Bombyx Batryticatus of 1.15 g, Curcumae Longae Rhizoma of 0.14 g, Cicadae Periostracum of 0.14 g, and Rhei Radix et Rhizoma of 2.3 g, with halved dosage applied for children. For the powder version of Shengjiangsan, the dosage varied in accordance with the severity of the disease. Bombyx Batryticatus of 1.84 g, Curcumae Longae Rhizoma of 0.28 g, Cicadae Periostracum of 0.92 g, and Rhei Radix et Rhizoma of 3.68 g were processed into powder for patients with mild symptoms. Bombyx Batryticatus of 2.48 g, Curcumae Longae Rhizoma of 0.37 g, Cicadae Periostracum of 1.23 g, and Rhei Radix et Rhizoma of 4.91 g were processed into powder for patients with severe symptoms. Bombyx Batryticatus of 3.68 g, Curcumae Longae Rhizoma of 1.84 g, Cicadae Periostracum of 0.55 g, and Rhei Radix et Rhizoma of 7.36 g were processed into powder for patients with critical conditions. In this formula, four herbs were ground to fine powder. For patients with mild symptoms, the whole formula was divided into four dosages, and each dosage weighed 6.71 g. The 200 mL yellow rice wine and 18.65 g honey were added, and the solution was stirred and taken cold till full recovery. For patients with severe symptoms, the whole formula was divided into three dosages, and each weighed 8.95 g. 300 mL yellow rice wine and 27.98 g honey were added, and the solution was stirred and taken cold. For patients with critical conditions, the whole formula was divided into two dosages, and each weighed 13.43 g. 400 mL yellow rice wine and 37.3 g honey were added, and the solution was stirred and taken cold. Shengjiangsan has the effect of ascending lucidity and descending turbidity, dissipating wind, and clearing heat. It is specialized in treating severe heat in exterior, interior, and triple energizers in warm diseases and has a wide modern clinical application. In this study, the historic evolution and key information of Shengjiangsan were reviewed and analyzed, and the key information table of Shengjiangsan was attached, serving as a reference for scholars' research and a theoretical basis for its market transformation.
3.An in vitro study of the impact of lead on dedifferentiation of mouse vascular smooth muscle cells
Jiaying HONG ; Suhui LIU ; Wenxi LIANG ; Qiying NONG ; Yongshun HUANG
Shanghai Journal of Preventive Medicine 2025;37(4):378-382
ObjectiveTo explore the role of lead exposure in the phenotypic transformation of vascular smooth muscle cells (VSMC), and to provide new insights for the mechanism of lead impact on vascular lesions. MethodsMouse aortic smooth muscle cells (MOVAS) were divided into a control group (0 μmol·L-1), low concentration lead groups (0.1, 1, 5, and 10 μmol·L-1), and high concentration lead groups (15, 25, and50 μmol·L-1). MTT assays were used to assess the proliferation of the cells, and scratch assays were implicated to measure migration ability of the cells. Fluorescence quantitative PCR was employed to determine levels of mRNA expression for smooth muscle actin α (α⁃SMA), smooth muscle 22 alpha (SM22α), synthetic phenotype-related genes osteopontin (OPN), matrix metalloproteinase 9 (MMP9), and the transcription factor SOX9. Immunoblotting was used to determine levels of protein expression for α-SMA, OPN, and MMP9. ResultsProliferation of MOVAS was observed under the lead ions concentrations of 0‒50 µmol·L-1, with a significant increase of proliferation compared to the control group at the concentrations of 5‒50 µmol·L-1 (all P<0.05). The migration ability of cells gradually increased at the concentrations of 0‒10 µmol·L-1, with a significant increase at 5 (q=4.574, P=0.003) and 10 µmol·L-1 (q=10.570, P<0.001) compared to the control group. The 10 µmol·L-1 lead ions significantly reduced the levels of mRNA expression for vascular smooth muscle contractile phenotype genes α⁃SMA (q=7.426, P<0.001) and SM22α (q=4.766, P=0.001), while significantly increasing the levels of mRNA expression for OPN (q=11.330, P<0.001), MMP9 (q=7.842, P<0.001), and SOX9 (q=11.120, P<0.001) genes. Furthermore, the 10 µmol·L-1 lead ions significantly reduced the levels of protein expression for the vascular smooth muscle contractile phenotype marker α-SMA protein (q=2.897, P=0.049), while significantly increasing the levels of protein expression for the synthetic markers OPN (q=3.188, P=0.031) and MMP9 (q=3.292, P=0.026), compared to the control group. ConclusionTreatment with lead in vitro induced VSMC to differentiate from contractile phenotype to synthetic phenotype, indicating that a certain dose of lead exposure might be detrimental to the cardiovascular system.
4.Textual Research and Ancient and Modern Application of Classical Prescription Sinisan
Lyuyuan LIANG ; Qing TANG ; Jialei CAO ; Wenxi WEI ; Yuxin ZHANG ; Jinyu CHEN ; Hejia WAN ; Chen CHEN ; Ruiting SU ; Bingqi WEI ; Shen'ao DING ; Bingxiang MA ; Wenli SHI
Chinese Journal of Experimental Traditional Medical Formulae 2025;31(18):182-193
Sinisan is a classical prescription developed and applied by ancient medical experts and it is first recorded in the Treatise on Cold Damage written by ZHANG Zhongjing in the Eastern Han Dynasty. Later physicians have modified this prescription based on this original one. The bibliometrics methods were used to analyze the key information and research trend of Sinisan. According to the inclusion and exclusion criteria, 69 pieces of effective data were extracted, involving 67 ancient traditional Chinese medicine (TCM) books. The results showed that the name, composition, and decocting methods of Sinisan in later generations were inherited from the original record in the Treatise on Cold Damage. The original plants of medicinal materials used in Sinisan are basically clear. We recommend Bupleuri Radix as the dried root of Bupleurem scorzonerifolium, Paeoniae Radix Alba as the dried root of Paeonia lactiflora, Aurantii Fructus as the dried fruit of Citrus aurantium, Glycyrrhizae Radix et Rhizoma as the dry root and rhizome of Glycyrrhiza uralensis. Raw materials of Bupleuri Radix and Paeoniae Radix Alba, Aurantii Fructus stir-fried with bran, and stir-fried Glycyrrhizae Radix et Rhizoma should be used for preparation of Sinisan. According to measurement system in the Han Dynasty, a bag of Sinisan is composed of 1.25 g Bupleuri Radix, 1.25 g Paeoniae Radix Alba, 1.25 g Aurantii Fructus, and 1.25 g Glycyrrhizae Radix et Rhizoma. The materials should be grounded into coarse powder and taken with a proper amount of rice soup, 3 times a day. Sinisan has the effects of regulating qi movement and harmonizing the liver and spleen. It can be used for treating reversal cold in limbs and cold damage. In modern clinical practice, Sinisan can be used to treat chronic gastritis, irritable bowel syndrome, and dyspepsia. The above research results provide scientific reference for the future research and development of Sinisan.
5.Expert consensus on pulpotomy in the management of mature permanent teeth with pulpitis.
Lu ZHANG ; Chen LIN ; Zhuo CHEN ; Lin YUE ; Qing YU ; Benxiang HOU ; Junqi LING ; Jingping LIANG ; Xi WEI ; Wenxia CHEN ; Lihong QIU ; Jiyao LI ; Yumei NIU ; Zhengmei LIN ; Lei CHENG ; Wenxi HE ; Xiaoyan WANG ; Dingming HUANG ; Zhengwei HUANG ; Weidong NIU ; Qi ZHANG ; Chen ZHANG ; Deqin YANG ; Jinhua YU ; Jin ZHAO ; Yihuai PAN ; Jingzhi MA ; Shuli DENG ; Xiaoli XIE ; Xiuping MENG ; Jian YANG ; Xuedong ZHOU ; Zhi CHEN
International Journal of Oral Science 2025;17(1):4-4
Pulpotomy, which belongs to vital pulp therapy, has become a strategy for managing pulpitis in recent decades. This minimally invasive treatment reflects the recognition of preserving healthy dental pulp and optimizing long-term patient-centered outcomes. Pulpotomy is categorized into partial pulpotomy (PP), the removal of a partial segment of the coronal pulp tissue, and full pulpotomy (FP), the removal of whole coronal pulp, which is followed by applying the biomaterials onto the remaining pulp tissue and ultimately restoring the tooth. Procedural decisions for the amount of pulp tissue removal or retention depend on the diagnostic of pulp vitality, the overall treatment plan, the patient's general health status, and pulp inflammation reassessment during operation. This statement represents the consensus of an expert committee convened by the Society of Cariology and Endodontics, Chinese Stomatological Association. It addresses the current evidence to support the application of pulpotomy as a potential alternative to root canal treatment (RCT) on mature permanent teeth with pulpitis from a biological basis, the development of capping biomaterial, and the diagnostic considerations to evidence-based medicine. This expert statement intends to provide a clinical protocol of pulpotomy, which facilitates practitioners in choosing the optimal procedure and increasing their confidence in this rapidly evolving field.
Humans
;
Calcium Compounds/therapeutic use*
;
Consensus
;
Dental Pulp
;
Dentition, Permanent
;
Oxides/therapeutic use*
;
Pulpitis/therapy*
;
Pulpotomy/standards*
6.Difficulties and Methodological Recommendations for Value-Based Pricing of Health Care Services
Leyi LIANG ; Qian PENG ; Yue YIN ; Wenxi TANG
Chinese Health Economics 2024;43(6):10-13
Objective:To explore the difficulties and methods of value-based pricing of healthcare services,and to provide references for the price management of healthcare services in China.Methods:Based on the analysis of literature and policy,the operational methods of value-based pricing are clarified,and the international application experience of value-based pricing is reviewed.Comprehensive field research and interviews are conducted to analyze the difficulties in applying value-based pricing to healthcare services.Results:Currently,there are no mature theories and methods for value-based pricing of healthcare services,and there are also many practical difficulties in financing,payment,assessment and evaluation policies.Conclusion:In the future,it should consider incorporating service experience into the value framework independently of utility,and take"service utility"as the basis for pricing healthcare services,and select relevant indicators for measurement.At the same time,the price of healthcare services should take into account the willingness to pay of multiple parties,and stakeholders need to work closely together to form a consensus on value.
7.Pricing of Healthcare Services:An Initial Exploration of Value-Based Pricing Transformation Methodology
Qian PENG ; Yue YIN ; Leyi LIANG ; Wenxi TANG
Chinese Health Economics 2024;43(6):14-17
Objective:Compared to pricing based on input value,pricing based on output can better motivate service outcomes towards expectations and enhance input-output efficiency.The path of outcome value-oriented pricing for healthcare services is explored to provide a theoretical foundation for the value-based pricing of healthcare services.Methods:The concepts,methods and international experience of value pricing are sorted out.Results:Outcome-based pricing in healthcare services is divided into effect and utility,and is classified into four categories based on the different emphasis on the effect and utility of healthcare services.Conclusion:Services with a strong emphasis on effectiveness can draw inspiration from the Quantified Quality of Life(QALY)results in the medical technology field,while services with a strong emphasis on utility may require the development of new utility scales for service evaluation.
8.Difficulties and Methodological Recommendations for Value-Based Pricing of Health Care Services
Leyi LIANG ; Qian PENG ; Yue YIN ; Wenxi TANG
Chinese Health Economics 2024;43(6):10-13
Objective:To explore the difficulties and methods of value-based pricing of healthcare services,and to provide references for the price management of healthcare services in China.Methods:Based on the analysis of literature and policy,the operational methods of value-based pricing are clarified,and the international application experience of value-based pricing is reviewed.Comprehensive field research and interviews are conducted to analyze the difficulties in applying value-based pricing to healthcare services.Results:Currently,there are no mature theories and methods for value-based pricing of healthcare services,and there are also many practical difficulties in financing,payment,assessment and evaluation policies.Conclusion:In the future,it should consider incorporating service experience into the value framework independently of utility,and take"service utility"as the basis for pricing healthcare services,and select relevant indicators for measurement.At the same time,the price of healthcare services should take into account the willingness to pay of multiple parties,and stakeholders need to work closely together to form a consensus on value.
9.Pricing of Healthcare Services:An Initial Exploration of Value-Based Pricing Transformation Methodology
Qian PENG ; Yue YIN ; Leyi LIANG ; Wenxi TANG
Chinese Health Economics 2024;43(6):14-17
Objective:Compared to pricing based on input value,pricing based on output can better motivate service outcomes towards expectations and enhance input-output efficiency.The path of outcome value-oriented pricing for healthcare services is explored to provide a theoretical foundation for the value-based pricing of healthcare services.Methods:The concepts,methods and international experience of value pricing are sorted out.Results:Outcome-based pricing in healthcare services is divided into effect and utility,and is classified into four categories based on the different emphasis on the effect and utility of healthcare services.Conclusion:Services with a strong emphasis on effectiveness can draw inspiration from the Quantified Quality of Life(QALY)results in the medical technology field,while services with a strong emphasis on utility may require the development of new utility scales for service evaluation.
10.Difficulties and Methodological Recommendations for Value-Based Pricing of Health Care Services
Leyi LIANG ; Qian PENG ; Yue YIN ; Wenxi TANG
Chinese Health Economics 2024;43(6):10-13
Objective:To explore the difficulties and methods of value-based pricing of healthcare services,and to provide references for the price management of healthcare services in China.Methods:Based on the analysis of literature and policy,the operational methods of value-based pricing are clarified,and the international application experience of value-based pricing is reviewed.Comprehensive field research and interviews are conducted to analyze the difficulties in applying value-based pricing to healthcare services.Results:Currently,there are no mature theories and methods for value-based pricing of healthcare services,and there are also many practical difficulties in financing,payment,assessment and evaluation policies.Conclusion:In the future,it should consider incorporating service experience into the value framework independently of utility,and take"service utility"as the basis for pricing healthcare services,and select relevant indicators for measurement.At the same time,the price of healthcare services should take into account the willingness to pay of multiple parties,and stakeholders need to work closely together to form a consensus on value.

Result Analysis
Print
Save
E-mail